FDA approves nivolumab for completely resected stage IIB/C melanoma
Metastatic subcutaneous melanoma Image courtesy of DermNetZ The treatment of patients with melanoma is undergoing a paradigm shift. In October 2023, the FDA approved nivolumab (Opdivo; Bristol Myers Squibb) for patients 12 years and older with completely resected stage IIB/C melanoma.1 This recent approval is considered a groundbreaking development for patients with advanced melanoma. Wide … Read more